Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK2340272A in Children 6-35 Months
NCT00971321Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Primary completion
- Nov 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Q-Pan H1N1 in pandemic influenza (2 arms), sponsored by GSK. Primary endpoints: Number of Seropositive Subjects for H1N1 Haemagglutination Inhibition (HI) Antibodies at Day 42, Titers for H1N1 Haemagglutination Inhibition (HI) Antibodies at Day 42 and 3 more. Started Sep 2009; status: completed.
02
Drugs
Q-Pan H1N1
03
Conditions
pandemic influenza
Beyond the preview
Go deeper on NCT00971321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00971321.